Literature DB >> 9130709

Regulation of CDK7 substrate specificity by MAT1 and TFIIH.

K Y Yankulov1, D L Bentley.   

Abstract

The cyclin-dependent kinase (CDK)-activating kinase CAK has been proposed to function in the control of cell cycle progression, DNA repair and RNA polymerase II (pol II) transcription. Most CAK exists as complexes of three subunits: CDK7, cyclin H (CycH) and MAT1. This tripartite CAK occurs in a free form and in association with 'core' TFIIH, which functions in both pol II transcription and DNA repair. We investigated the substrate specificities of different forms of CAK. Addition of the MAT1 subunit to recombinant bipartite CDK7-CycH switched its substrate preference to favour the pol II large subunit C-terminal domain (CTD) over CDK2. We suggest that the MAT1 protein, previously shown to function as an assembly factor for CDK7-CycH, also acts to modulate CAK substrate specificity. The substrate specificities of natural TFIIH and free CAK were also compared. TFIIH had a strong preference for the CTD over CDK2 relative to free CAK. TFIIH, but not free CAK, could efficiently hyperphosphorylate the CTD. In the context of TFIIH, the kinase also acquired specificity for the general transcription factors TFIIE and TFIIF which were not recognized by free CAK. We conclude that the substrate preference of the CDK7-CycH kinase is governed by association with both MAT1 and 'core' TFIIH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130709      PMCID: PMC1169768          DOI: 10.1093/emboj/16.7.1638

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  37 in total

Review 1.  Principles of CDK regulation.

Authors:  D O Morgan
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

2.  The transcriptional elongation inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase.

Authors:  K Yankulov; K Yamashita; R Roy; J M Egly; D L Bentley
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

3.  A mammalian RNA polymerase II holoenzyme containing all components required for promoter-specific transcription initiation.

Authors:  V Ossipow; J P Tassan; E A Nigg; U Schibler
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

4.  KIN28 encodes a C-terminal domain kinase that controls mRNA transcription in Saccharomyces cerevisiae but lacks cyclin-dependent kinase-activating kinase (CAK) activity.

Authors:  M J Cismowski; G M Laff; M J Solomon; S I Reed
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

5.  Cdk-activating kinase complex is a component of human transcription factor TFIIH.

Authors:  R Shiekhattar; F Mermelstein; R P Fisher; R Drapkin; B Dynlacht; H C Wessling; D O Morgan; D Reinberg
Journal:  Nature       Date:  1995-03-16       Impact factor: 49.962

6.  Association of Cdk-activating kinase subunits with transcription factor TFIIH.

Authors:  H Serizawa; T P Mäkelä; J W Conaway; R C Conaway; R A Weinberg; R A Young
Journal:  Nature       Date:  1995-03-16       Impact factor: 49.962

7.  The KIN28 gene is required both for RNA polymerase II mediated transcription and phosphorylation of the Rpb1p CTD.

Authors:  J G Valay; M Simon; M F Dubois; O Bensaude; C Facca; G Faye
Journal:  J Mol Biol       Date:  1995-06-09       Impact factor: 5.469

8.  p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.

Authors:  L Zhu; E Harlow; B D Dynlacht
Journal:  Genes Dev       Date:  1995-07-15       Impact factor: 11.361

9.  Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase.

Authors:  O Aprelikova; Y Xiong; E T Liu
Journal:  J Biol Chem       Date:  1995-08-04       Impact factor: 5.157

10.  MAT1 ('menage à trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK.

Authors:  A Devault; A M Martinez; D Fesquet; J C Labbé; N Morin; J P Tassan; E A Nigg; J C Cavadore; M Dorée
Journal:  EMBO J       Date:  1995-10-16       Impact factor: 11.598

View more
  62 in total

1.  hnRNP U inhibits carboxy-terminal domain phosphorylation by TFIIH and represses RNA polymerase II elongation.

Authors:  M K Kim; V M Nikodem
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Differential control of transcription by DNA-bound cyclins.

Authors:  T Y Kim; W G Kaelin
Journal:  Mol Biol Cell       Date:  2001-07       Impact factor: 4.138

3.  Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH.

Authors:  M Rossignol; I Kolb-Cheynel; J M Egly
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

Review 4.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

5.  Inhibition of HTLV-1 transcription by cyclin dependent kinase inhibitors.

Authors:  Lai Wang; Longwen Deng; Kaili Wu; Cynthia de la Fuente; Dai Wang; Kylene Kehn; Anil Maddukuri; Shanese Baylor; Francisco Santiago; Emmanuel Agbottah; Sylviane Trigon; Michel Morange; Renaud Mahieux; Fatah Kashanchi
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

6.  T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity.

Authors:  S Larochelle; J Chen; R Knights; J Pandur; P Morcillo; H Erdjument-Bromage; P Tempst; B Suter; R P Fisher
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

7.  Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

Authors:  Rong Chen; William G Wierda; Sherri Chubb; Rachael E Hawtin; Judith A Fox; Michael J Keating; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

8.  Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities.

Authors:  P Kaldis; A A Russo; H S Chou; N P Pavletich; M J Solomon
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

9.  Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Authors:  Nadine Löschmann; Martin Michaelis; Florian Rothweiler; Richard Zehner; Jaroslav Cinatl; Yvonne Voges; Mohsen Sharifi; Kristoffer Riecken; Jochen Meyer; Andreas von Deimling; Iduna Fichtner; Taravat Ghafourian; Frank Westermann; Jindrich Cinatl
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  DNA repair and transcriptional effects of mutations in TFIIH in Drosophila development.

Authors:  Carlos Merino; Enrique Reynaud; Martha Vázquez; Mario Zurita
Journal:  Mol Biol Cell       Date:  2002-09       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.